Ethylene Oxide (EO) Sterilization: Value, Risks, And Industry Trends Analysis

Ethylene Oxide (EO) Sterilization: Value, Risks, and Industry Trends Behind its Widespread Application

In the medical device and pharmaceutical industries, sterilization processes are directly related to product safety and compliance. Ethylene oxide (EO) sterilization, due to its unique advantages, has long held a core position in global medical device sterilization technology. However, with increasingly stringent regulations and heightened safety awareness, EO sterilization has gradually become a "highly efficient but controversial" technology. This article will systematically analyze EO sterilization from the perspectives of application value, risk controversies, regulatory oversight, ventilation control, and future trends.

 

I. The Role and Application of Ethylene Oxide (EO) in Sterilization

Ethylene oxide sterilization is currently one of the most commonly used sterilization methods for medical devices globally. In the US market, besides EO sterilization and radiation sterilization, only about 5–10% of medical devices use other sterilization methods, a figure that fully demonstrates the irreplaceable nature of EO in the industry.

The greatest advantage of EO sterilization lies in its low-temperature sterilization characteristics. Compared to high-temperature steam or radiation methods, EO can efficiently kill microorganisms under lower temperature and humidity conditions without damaging the material structure and performance. Therefore, it is widely used in medical devices highly sensitive to heat, radiation, and humidity, such as: various catheters, stents, artificial prostheses, and other implantable or invasive devices; medical electronic products, such as pacemakers, insulin pumps, and sensing devices; disposable medical consumables, such as medical gloves, masks, and infusion kits; and the sterilization of the outer packaging and container surfaces of certain pharmaceuticals or medical devices.

Due to its high penetrability, strong material compatibility, and wide applicability, EO sterilization remains difficult to completely replace under current technological conditions.

 

II. Hazards and Controversies: Safety Hazards Behind High Efficiency

Despite the significant technological advantages of EO sterilization, its safety remains a major concern. Ethylene oxide itself is a highly hazardous chemical gas, clearly identified as carcinogenic, mutagenic, and reproductively toxic (CMR), and also possesses colorless, flammable, and explosive properties. After sterilization, excipients (EO) may remain inside or on the surface of medical device materials and further transform into the following byproducts: Ethylenechlorohydrin (ECH) and Ethylene glycol (EG). All three substances pose potential health risks, and improper residue control can cause long-term harm to patients, healthcare workers, and users. This is the core source of the controversy surrounding EO sterilization.

 

III. Regulations and Regulation: Tightening Globally

Due to the high-risk nature of EO, regulatory agencies in various countries are continuously strengthening their control.

In the EU system, EO is officially classified as a CMR substance and is subject to multiple regulations including REACH, CLP, and the Medical Device Regulation (MDR). The EU has also clearly stated at the policy level that it may further restrict the use of EO in the future and actively promote the development of alternative sterilization technologies.

For enterprises, EO sterilization is no longer just a "technical issue," but a systemic problem highly intertwined with compliance, environmental protection, and social responsibility.

 

IV. Aeration: A Crucial Stage in EO Sterilization

Due to the risk of EO residue, the aeration stage is a vital part of the EO sterilization process. Its core objective is to release EO and its reaction byproducts from the product and reduce them to safe levels.

International standard ISO 10993-7 clearly specifies the permissible residue limits for EO, ​​ECH, and EG, and sets them differently based on the product's target population, usage method, and exposure time.

The aeration effect is not constant but is affected by various factors, including:
* Temperature and time of the aeration environment
* Stacking density and structural configuration of the product in the aeration chamber
* Airflow organization and circulation efficiency
* The adsorption characteristics of the material itself for EO
* Packaging materials and their permeability
* Improper control of any of these factors can lead to excessive residues.

 

V. Validation and Process Control of the Aeration Stage

To ensure the stability and repeatability of the aeration process, the industry commonly uses **aeration validation** for management.

Typically, companies need to demonstrate that their ventilation scheme is controllable and consistent in long-term production through data analysis of at least three complete sterilization and ventilation cycles. Simultaneously, the validation process must focus on evaluating the "worst case," such as the ventilation effect under maximum load and most dense stacking conditions.

Furthermore, the sampling location, timing, and method for residual testing samples must be rigorously designed; otherwise, even if the test data is qualified, it may not be representative.

 

VI. Time and Cost: Undeniable Real-World Challenges
Ventilation time varies significantly depending on material characteristics, product structure, and sterilization parameters, ranging from a few hours to several days. Longer ventilation times not only extend delivery cycles but also significantly increase energy, space, and operating costs.

This is one of the key reasons why EO sterilization faces "dual pressures of cost and compliance" in the current environment.

 

VII. Future Trends: Stricter Standards and Risk-Oriented Approaches Go Hand in Hand

As safety standards continue to evolve, ISO 10993-7 is undergoing revision, with key directions including:
Introducing more flexible, risk-based methods for assessing residue limits
Providing clearer guidance for product release and residue determination
Strengthening the explanation of residue formation mechanisms and influencing factors
Future standards are likely to further reduce permissible residue levels, for example, by using risk calculations based on lower body weight assumptions. This will place higher demands on the design and management of EO sterilization systems.

 

Conclusion
Ethylene oxide sterilization will remain an indispensable key technology in the medical device industry in the short term, but its application has shifted from "efficiency first" to "equal emphasis on safety, compliance, and risk control." For companies, only continuous investment in technological capabilities, regulatory understanding, and process control can maintain competitiveness in an increasingly stringent global regulatory environment.